 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for...

Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial

The study, published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog Benefits are thought to include a...

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Psyence Biomedical gets non-compliance notification from Nasdaq...

Psyence Biomedical gets non-compliance notification from Nasdaq

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the Company ) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications...

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Psyence Biomedical says 'foundation in place' to be R&D leader in psilocybin

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental...

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in...

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

TORONTO, March 11, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc ("Psyence Group" or the "Company") (CSE:PSYG) of the closing (the "Closing") of the business combination...

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

Gagnants
Le titre Psyence Biomedical (NASDAQ:PBM) a grimp vendredi de 146,36% 3,13 dollars lors de la session ordinaire.
L'action Ainos (NASDAQ:AIMD) a grimp de 88,36% 2,11 dollars.
Le titre...

12 titres de soins de sant  en mouvement lors de la session du 08/03/2024

Titoli in rialzo
Il titolo Psyence Biomedical (NASDAQ:PBM) ha osservato un incremento del 140,94% a 3,06 dollari durante la sessione regolare di venerd .
Il titolo Ainos (NASDAQ:AIMD) ha avuto un...

12 titoli sanitari in movimento, sessione regolare del 08/03/2024

Psyence Biomedical Ltd. is a life science biotechnology company. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company was founded on June 29, 2023 and is headquartered in Toronto, Canada.

Volume (M)	23,488.00
52-Wk High	$4.31
52-Wk Low	$0.5135

PBM Psyence Biomedical Ltd.

About

Feed

News

Sentiment

Fundamentals